Qilu Pharmaceutical always adheres to the strategy of innovation and development, takes market demand as the core, takes product innovation as the guidance, extensively expands domestic and international scientific research and development cooperation, pays attention to the introduction and cultivation of talents, builds a high-quality scientific research team with professional and efficient research and development capabilities, and establishes a reasonable product line under research for the company's future development. Dozens of small molecular drugs, new pharmaceutical preparations, recombinant proteins, synthetic peptides and anti-tumor vaccines, including brand-new molecular structures, are being developed at different stages, including clinical research.
Qilu Pharmaceutical has seven production bases, including preparation, chemical synthesis, biotechnology and antibiotic fermentation, covering an area of 6.5438+0.9 million square meters. The company's automatic production line and other major production equipment and testing instruments are purchased from the world's major professional pharmaceutical equipment manufacturers. The production of APIs includes fermentation, chemical synthesis, biochemical synthesis, genetic engineering, freeze-drying and solvent crystallization. Powder injection, freeze-dried powder injection, small volume injection, tablets, capsules, granules, creams, sprays, eye drops and other products are complete and reasonable.
The company has established a strict and standardized quality control organization and a perfect quality assurance system while establishing a strong pharmaceutical R&D and production capacity. It is one of the first GMP certified enterprises of the US Food and Drug Administration. Among them, non-sterile APIs (fermentation, chemical synthesis), sterile APIs and various preparations have passed the certification of national drug regulatory agencies such as the US Food and Drug Administration (USFDA), the European Drug Quality Committee (EDQM), the British MHRA and the South African Drug Administration (MCC).
Qilu Pharmaceutical has a professional marketing team, attaches great importance to the academic promotion and brand building of products, and has established a wide-ranging win-win cooperation relationship. Anti-infection, anti-tumor, cardiovascular and cerebrovascular products are highly recognized by clinical users, and the market share of products continues to increase rapidly. Besides having a nationwide sales network, the company also actively expands the international market, and its products are exported to Europe, North America, South America and Southeast Asia.
The company has successfully developed nearly 100 national-level new drugs, such as Shen Jie, Saizhen, Bai Rui, Juhezi, Dobutamine, Bangda, Lin Si, Ousai, Wen Yue and Suli, which provide a wide range of effective drugs for the treatment of major diseases that endanger health. The company's research has won national and provincial scientific and technological progress awards and created good social benefits.
Since 1992, Qilu Pharmaceutical has successively won the honorary titles of "Top 50 Pharmaceutical Industries in China", "Top 500 Pharmaceutical Industries in China 100", "Top 500 Industrial Enterprises with Best Economic Benefits in China", "Top High-tech Enterprises in China 100" and "National May 1 Labor Award". In 2006, it was jointly recognized as "National Enterprise Technology Center" by the National Development and Reform Commission and other five ministries and commissions, and was named as "the first top 500 competitive enterprises of China Enterprise Group" by the National Bureau of Statistics. It is one of the top ten pharmaceutical enterprises with the most growth, and one of the top 100 innovative pharmaceutical enterprises in China in 2006. In 2008, it was recognized as "National Engineering Laboratory" by the National Development and Reform Commission. In 2009, he won the honors of "30-year industry contribution award of pharmaceutical industry" and "AAA enterprise with enterprise credit evaluation"; 20 10 was awarded the title of "Top Ten Internationalized Pharmaceutical Enterprises"; 201/kloc-0 was awarded the title of "Top 100 Enterprises in Chemical Pharmaceutical Industry" (No.:6 1